HIV Management and Research


Dr. Bedimo studies strategies for optimally managing drug-resistant HIV patients, analyzing metabolic abnormalities in HIV patients, and studying the effects of HCV co-infection. 

Presently, the latest cutting-edge antiviral therapies are available through expanded access programs, and interested patients are offered the opportunity to join in national multicenter clinical trials and novel pilot studies being performed locally.  Research is an important part of HIV care, both to learn more about how to treat this infection, and to bring the latest advances to our patients. 

Current studies

  • Novel therapies for patients with drug-resistant HIV
  • Studies of lipid risk factors, prevention and management of dyslipidemia, lipodystrophy, and bone mineral loss among HIV-infected patients
  • Analysis of the trends of Non-AIDS-defining malignancies among HIV-infected patients comparing incidences pre-and post Highly Active Anti-retroviral Therapy (HAART), and analysis of factors associated with increased risk
  • Studies of simplified combination therapy and novel immune-based therapy
  • Laboratory-based research to understand the mechanisms of dyslipidemia among HIV and HIV/HCV co-infected patients

Featured Publications

Contact Us

Roger Bedimo, M.D., M.S., FACP
Associate Professor, Internal Medicine
Chief, Infectious Disease Section
VA North Texas Health Care System

Mailing Address

VAMC Office Phone: (214) 857-0397
UTSW Office Phone: (214) 648-9914 
Pager: 214-759-3154